Loading Events

Biotech + Breaking Glass: Leading Women in Life Sciences

Tuesday, Jan 24, 2023
Virtual – Zoom webinar

Webinar logo

Cooley’s Biotech + Breaking Glass: Leading Women in Life Sciences series features women in the life sciences industry sharing and celebrating their stories, obstacles and milestones.


Vice President of New Chemical Entity (NCE) Molecular Discovery @GSK


Innovation Fund Partner @Mass General Brigham
Meredith is a Partner with the Innovation Fund focusing on early stage investments and company creation. Previously, she was in the private/family office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development of Enlight Biosciences- a venture creation company founded by PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals (formerly, Scriptgen). Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE). Meredith is a member of the Board of Directors at Metera.
photo of Madison Jones

Partner @Cooley
Madison Jones practices corporate and securities law, representing late-stage private and publicly traded companies and underwriters, with a particular emphasis on capital markets transactions within two of the most rapidly growing industries: technology and life sciences. She has extensive experience counseling clients on the full range of general corporate and securities matters, including IPOs, public offerings, strategic corporate relationships, SEC reporting and compliance and corporate governance.

Partner @Cooley
Courtney T. Thorne’s practice focuses on the representation of public companies and investment banks in the life sciences industry, with an emphasis on capital raising, public company counseling, foreign private issuer matters and securities law compliance. In addition to a robust US practice, she has substantial expertise advising non-US companies (known as foreign private issuers or FPIs) seeking to access the US capital markets or to list on a US securities exchange. Over the past six years, Courtney has advised 45+ IPOs and follow-on offerings, with an aggregate value of over $4.2 billion.   



12:00 pm PT // 3:00 pm ET // 1 pm MST